Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
EF Hutton analyst Jason Kolbert maintains Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $6 price target.
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.0...
Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refracto...
EF Hutton analyst Jason Kolbert maintains Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $6 price target.
Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc.Citius Pharmace...
EF Hutton analyst Jason Kolbert initiates coverage on Citius Pharma (NASDAQ:CTXR) with a Buy rating and announces Price Targ...
Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline r...
